"Every newborn baby deserves
the best start into the future!"

InfanDx AG is a privately held company established in 2010 in Cologne, Germany, that focuses on the development and commercialization of diagnostic solutions for newborns. The proprietary lead product in clinical development is the InfanDx HypoxE-test® for the rapid and reliable diagnosis of perinatal asphyxia (oxygen deficit during birth) and early identification of hypoxic-ischemic encephalopathy (HIE), brain injuries that can result in life-long disabilities. While standard-of-care diagnostic methods cannot deliver a conclusive diagnosis of HIE within this time frame, the rapid InfanDx HypoxE-test® is designed to aid clinicians in the timely decision, which newborns require neuroprotective hypothermia treatment, a burdensome but effective therapy for mitigating and even preventing lasting brain. damage and associated disabilities.

InfanDX